- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.06. | Regentis Biomaterials to raise $6.5M via private placement | 1 | Seeking Alpha | ||
| 18.06. | Regentis Biomaterials Ltd: Regentis Biomaterials Announces Pricing of a $6.5 Million Private Placement | 574 | ACCESS Newswire | HERZLIYA, IL / ACCESS Newswire / June 17, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions... ► Artikel lesen | |
| 16.06. | Regentis Biomaterials Slips 9% After Soaring 506% On Monday - Here's Why RGNT Stock Is Trending | 5 | Benzinga.com | ||
| 15.06. | REGENTIS BIOMATERIALS LTD. - 6-K, Report of foreign issuer | 6 | SEC Filings | ||
| 09.06. | REGENTIS BIOMATERIALS LTD. - F-1/A, Registration statement for certain foreign private issuers | 5 | SEC Filings | ||
| 08.06. | REGENTIS BIOMATERIALS LTD. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 08.06. | Regentis Biomaterials Ltd: Regentis to Commence European Surgeon Training for GelrinC in Knee Cartilage Repair as Commercial Launch Preparations Accelerate | 482 | ACCESS Newswire | GelrinC, positioned as the first off-the-shelf cell-free hydrogel implant for knee cartilage repair, is approved for sale in the European UnionRegentis is growing its network of European Centers of... ► Artikel lesen | |
| REGENTIS BIOMATERIALS Aktie jetzt für 0€ handeln | |||||
| 28.05. | REGENTIS BIOMATERIALS LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 01.05. | REGENTIS BIOMATERIALS LTD. - F-1, Registration statement for certain foreign private issuers | 3 | SEC Filings | ||
| 16.04. | Regentis Biomaterials Ltd: Regentis Implements Strategy for Commercial Deployment of GelrinC in Europe Through Collaboration with Humanitas Hospital and Leading Cartilage Repair Expert Prof. Elizaveta Kon | 1.222 | ACCESS Newswire | Collaboration with leading European orthopedic center in Italy supports GelrinC clinical adoptionRenowned cartilage regeneration expert Prof. Elizaveta Kon to help lead Regentis Centers of Excellence... ► Artikel lesen | |
| 17.03. | Regentis Biomaterials Ltd: Regentis Biomaterials Develops and Patents New Solvent-Free Manufacturing Process That Increases GelrinC Production Yield by 400% | 429 | ACCESS Newswire | Breakthrough manufacturing process comes in preparation for upcoming commercial launch in Europe planned for later this yearProprietary process is already patented in several countries and is pending... ► Artikel lesen | |
| 24.02. | REGENTIS BIOMATERIALS LTD. - 20-F, Annual and transition report of foreign private issuers | 3 | SEC Filings | ||
| 24.02. | Regentis Biomaterials Ltd: Regentis Biomaterials Reports 2025 Financial Results and Provides Business Update | 860 | ACCESS Newswire | $7.4 million in cash expected to provide runway to complete site expansion process and patient enrollment as part of pivotal Phase III FDA trial for GelrinCAlready approved in Europe, GelrinC is expected... ► Artikel lesen | |
| 24.02. | REGENTIS BIOMATERIALS LTD. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 24.02. | Regentis Biomaterials (RGNT) Appoints New CFO/CBO as GelrinC Nears Commercial Launch | 4 | Insider Monkey | ||
| 19.02. | Regentis Biomaterials Ltd: Regentis Biomaterials Appoints Dr. Galit Reske as Chief Medical Officer: Brings Strong Track Record of Success in Cartilage Repair | 412 | ACCESS Newswire | Dr. Reske has proven leadership in clinical development and regulatory affairs following key role in FDA approval of cartilage repair product Agili-C leading to CartiHeal's $330 million acquisition... ► Artikel lesen | |
| 17.02. | REGENTIS BIOMATERIALS LTD. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 17.02. | Regentis Biomaterials Ltd: Regentis Expands its European Clinical Site Network to Support its Commercial and Clinical Programs | 695 | ACCESS Newswire | With CE Mark approval, GelrinC is slated for commercial launch in Europe in 2026New clinical sites to support engagement with leading orthopedic surgeons and centers of excellence in key European markets... ► Artikel lesen | |
| 04.02. | Regentis Biomaterials appoints new CFO | 1 | Seeking Alpha | ||
| 04.02. | Regentis Biomaterials Ltd: Regentis Biomaterials Appoints Ori Gon as Chief Financial Officer and Chief Business Officer as GelrinC Progresses Towards Commercial Launch in Europe and Advances in U.S. Phase III FDA Trial | 476 | ACCESS Newswire | GelrinC, the only restorative product for knee cartilage repair, has CE Mark approval in Europe and is currently at the midpoint of a pivotal FDA Phase III trial in the U.S.Ori Gon brings substantial... ► Artikel lesen |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 51,56 | +5,22 % | Ein starkes Duo in einem riesigen und ignorierten Wachstumsmarkt: MustGrow Biologics und Bayer, wann ist BayWa über den Berg? | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics Corp. Die globale Landwirtschaft befindet sich in einem tiefgreifenden Strukturwandel. Der Klimawandel mit Hitzewellen, Dürren und Extremwetterereignissen... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 66,54 | 0,00 % | Motorola Solutions Foundation and Calculated Genius Honor Chicagoland Future Engineers With 2026 Bright Minds, Bold Futures Scholarship | NORTHAMPTON, MA / ACCESS Newswire / June 30, 2026 / Ten extraordinary Chicagoland high school seniors recently gathered at Motorola Solutions' global headquarters in Chicago, joined by family members... ► Artikel lesen | |
| MERCK KGAA | 146,85 | +1,63 % | EQS-Adhoc: Merck KGaA: Merck vereinbart Akquisition von Bio-Techne Corporation | EQS-Ad-hoc: Merck KGaA / Schlagwort(e): Mergers und Acquisitions / Fusion
Merck KGaA: Merck vereinbart Akquisition von Bio-Techne Corporation
25.06.2026 / 11:33 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| KARDIGAN | 23,820 | -1,20 % | Kardigan, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Kardigan, Inc. (Nasdaq: KARD) ("Kardigan"), a clinical-stage precision therapeutics company developing medicines that target the root... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 36,630 | 0,00 % | Eton Pharmaceuticals Aktie erreicht Rekordhoch von 36,97 USD | ||
| GENERATE BIOMEDICINES | 16,520 | +0,12 % | Generate:Biomedicines: Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update | SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance
Clinical trial sites activated for GB-4362 (MMAE neutralizer); first... ► Artikel lesen | |
| PMGC | 1,280 | 0,00 % | PMGC Holdings Inc.: NorthStrive Biosciences Announces Positive Results from Phase III of AI-Driven Drug Discovery Program with Yuva Biosciences | Yuva Biosciences' proprietary MitoNova AI platform identified small-molecule candidates that were biologically validated in primary human skeletal muscle cells, with multiple candidates increasing... ► Artikel lesen | |
| LB PHARMACEUTICALS | 31,910 | +0,06 % | LB Pharmaceuticals Inc: LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations | NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,235 | -0,12 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Reaffirms guidance to resubmit Anaphylm (dibutepinephrine) sublingual film NDA in Q3 2026Affirms existing clinical data is sufficient for submitting regulatory applications in Canada, European Union... ► Artikel lesen | |
| PFIZER | 20,995 | -0,02 % | Pfizer-Aktie: Darum ist sie jetzt ein klarer Kauf | Die Aktie des US-Pharmakonzerns Pfizer rückt nach einem Kursrücksetzer wieder stärker in den Fokus einkommensorientierter Anleger. Ausschlaggebend ist vor allem die außergewöhnlich hohe Dividendenrendite... ► Artikel lesen | |
| NOVO NORDISK | 43,280 | -0,02 % | Börsen-Thriller 2026: Novo Nordisk "schwitzt", die Deutsche Telekom an der 26-EUR-Schwelle und das Antimon Juwel Antimony Resources greift an! | Erstellt und veröffentlicht im Auftrag von Antimony Resources Corp. Die Börsenwelt momentan ist voller Extreme. Während beispielsweise Novo Nordisk, ein ehemaliger Highflyer und einst wertvollster Konzern... ► Artikel lesen | |
| INHIBIKASE THERAPEUTICS | 1,935 | -0,26 % | Inhibikase Therapeutics, Inc. - 8-K, Current Report | ||
| KAZIA THERAPEUTICS | 13,405 | +0,11 % | BTIG initiates Kazia Therapeutics stock with buy on cancer drug | ||
| UNIVERSE PHARMACEUTICALS | 5,520 | -0,72 % | Morning Market Movers: Universe Pharmaceuticals, Decoy Therapeutics, Comcast, Larimar Therapeutics See Big Swings | PHILADELPHIA (dpa-AFX) - At 7:40 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ONKURE THERAPEUTICS | 4,460 | 0,00 % | OnKure Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans |
Das Unternehmen REGENTIS BIOMATERIALS LTD kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 4,510 Euro und damit -0,44 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu REGENTIS BIOMATERIALS LTD finden Sie auf Wallstreet Online.